Quantcast
Last updated on April 24, 2014 at 16:34 EDT

Latest Ventricular remodeling Stories

2013-05-23 08:27:51

Clinical program supports accelerated approval filing with CFDA in China, and a Phase 3 program in the U.S. SAN DIEGO and SHANGHAI, May 23, 2013 /PRNewswire/ -- Zensun Sci & Tech, Ltd., a biopharmaceutical company based in Shanghai and San Diego, announced today positive results of four completed Phase 2 clinical trials including three double-blind, placebo-controlled studies conducted in China and Australia and interim results from the United States Phase 2 trial for Zensun's...

2013-05-02 08:37:14

-- Phase II, randomized, placebo-controlled study at Glenfield Hospital, University of Leicester (UK) will measure primary efficacy endpoint of change from baseline in left ventricular ejection fraction (LVEF) post-percutaneous coronary intervention (PCI) -- TORONTO, May 2, 2013 /PRNewswire/ -- CellAegis Devices, Inc., announced today the first clinical trial program in the European Union to evaluate the use of the Company's autoRIC(TM) Device for Chronic Remote Ischemic Conditioning...

2013-03-07 12:27:38

- Health Canada Medical Device Class III license covers broad applications in cardiovascular disease, including for patients undergoing cardiothoracic surgery, interventional cardiothoracic procedures, or patients who have evolving myocardial infarction - TORONTO, March 7, 2013 /PRNewswire/ -- CellAegis Devices, Inc. announced today that it has received marketing authorization from Health Canada that allows for the commercial introduction in Canada of the Company's autoRIC(TM)...

2013-02-27 08:28:34

-- Phase II, randomized, placebo-controlled, multi-center study will measure the primary efficacy endpoint of reduction in ventricular remodeling post-percutaneous coronary intervention (PCI) -- TORONTO, Feb. 27, 2013 /PRNewswire/ -- CellAegis Devices, Inc., announced today that it has received an Investigational Testing Approval (ITA) from Health Canada that allows the initiation of clinical testing in Canada of the Company's autoRIC(TM) Device for Chronic Remote Ischemic...

2013-02-20 16:25:22

SAN DIEGO, Feb. 20, 2013 /PRNewswire/ -- Ventrix, Inc. announced today that its VentriGel((TM)) cardiac repair scaffold safely and effectively mitigated left ventricular remodeling and improved cardiac function in pigs after myocardial infarction, or heart attack. The findings, made during pre-clinical studies, were published today in the journal Science Translational Medicine. Based on these and other results, Ventrix will initiate a first-in-man clinical trial for VentriGel later this...

2012-01-03 06:00:00

HAMPTON, N.J., Jan. 3, 2012 /PRNewswire/ -- Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients in the hospital and ICU settings, today announced that it has commenced its global development program, the PRESERVATION I clinical trial, for its Bioabsorbable Cardiac Matrix (BCM). The CE Mark registration trial has commenced in Australia, and will be followed in Europe. The trial also is expected to commence in other...

2011-12-07 14:38:08

"Up until now infarct size has only been measured as part of clinical studies and not in routine clinical practice. The reason being that the reference method of gadolinium based contrast agents in MRI is expensive, takes a great deal of time to perform, and can only be undertaken by imaging specialists," explains EAE president Dr Luigi Badano, from the University of Padua, Italy. "The advantages of STE over MRI is that it's far quicker to use, cheaper, and can be used by cardiologists at the...

2011-06-27 21:28:51

Clarifying terminology will help foster communication between different investigators The European Society of Cardiology (ESC) Working Group on Myocardial Function is calling for a redefinition of the term cardiac hypertrophy which is currently used to describe changes to the morphology (structure) of the heart. Instead the position paper, published online today in the European Journal of Heart Failure, suggests that use of the general term myocardial remodelling should be preferred. "We hope...

2010-12-21 07:30:00

ALLENDALE, N.J., Dec. 21, 2010 /PRNewswire/ -- The American Heart Journal today reported results of a clinical trial evaluating Amorcyte, Inc.'s lead product candidate, AMR-001 for the treatment of damaged heart muscle following acute myocardial infarction (AMI). Data demonstrated a significant relationship between cell dose and biologic effect. This is the first and only study to prospectively define a dose of a purified and potent autologous (self-donating) stem cell therapy that...

2010-09-14 22:18:49

The first randomized, placebo-controlled U.S. clinical trial to assess the use of bone marrow-derived mononuclear cells (BMC) in patients after a ST-elevation myocardial infarction (STEMI; severe heart attack) demonstrated a strong safety profile for this cell therapy, based on phase 1 results published in the September issue of the American Heart Journal. "The use of adult stem cells, derived from the patient's own bone marrow, presents a potential new type of therapy to benefit individuals...